The current challenges faced by people with hemophilia B
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd..
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma-derived products. For people with severe HB, lifelong prophylaxis with a FIX replacement product is standard of care. Development of extended half-life FIX replacement products has allowed for advancements in the care of these PWHB. Nonetheless, lifelong need for periodic dosing and complex surveillance protocols pose substantive challenges in terms of access, adherence, and healthcare resource utilization. Further, some PWHB on prophylactic regimens continue to experience breakthrough bleeds and joint damage, and subpopulations of PWHB, including women, those with mild-to-moderate HB, and those with inhibitors to FIX, experience additional unique difficulties. This review summarizes the current challenges faced by PWHB, including the unique subpopulations; identifying the need for improved awareness, personalized care strategies, and new therapeutic options for severe HB, which may provide future solutions for some of the remaining unmet needs of PWHB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
European journal of haematology - 112(2024), 3 vom: 26. Feb., Seite 339-349 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miesbach, Wolfgang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9001-28-9 |
|---|
| Anmerkungen: |
Date Completed 19.02.2024 Date Revised 19.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.14135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365732974 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365732974 | ||
| 003 | DE-627 | ||
| 005 | 20240219231929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.14135 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1299.xml |
| 035 | |a (DE-627)NLM365732974 | ||
| 035 | |a (NLM)38082533 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miesbach, Wolfgang |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The current challenges faced by people with hemophilia B |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2024 | ||
| 500 | |a Date Revised 19.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. | ||
| 520 | |a Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma-derived products. For people with severe HB, lifelong prophylaxis with a FIX replacement product is standard of care. Development of extended half-life FIX replacement products has allowed for advancements in the care of these PWHB. Nonetheless, lifelong need for periodic dosing and complex surveillance protocols pose substantive challenges in terms of access, adherence, and healthcare resource utilization. Further, some PWHB on prophylactic regimens continue to experience breakthrough bleeds and joint damage, and subpopulations of PWHB, including women, those with mild-to-moderate HB, and those with inhibitors to FIX, experience additional unique difficulties. This review summarizes the current challenges faced by PWHB, including the unique subpopulations; identifying the need for improved awareness, personalized care strategies, and new therapeutic options for severe HB, which may provide future solutions for some of the remaining unmet needs of PWHB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Hemophilia B | |
| 650 | 4 | |a coagulation factor IX | |
| 650 | 4 | |a quality of life | |
| 650 | 7 | |a Factor IX |2 NLM | |
| 650 | 7 | |a 9001-28-9 |2 NLM | |
| 700 | 1 | |a von Drygalski, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Clive |e verfasserin |4 aut | |
| 700 | 1 | |a Sivamurthy, Krupa |e verfasserin |4 aut | |
| 700 | 1 | |a Pinachyan, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Bensen-Kennedy, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a Drelich, Douglass |e verfasserin |4 aut | |
| 700 | 1 | |a Kulkarni, Roshni |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 112(2024), 3 vom: 26. Feb., Seite 339-349 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2024 |g number:3 |g day:26 |g month:02 |g pages:339-349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.14135 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2024 |e 3 |b 26 |c 02 |h 339-349 | ||